DEA Procedural Delay Triggers Cannabis Stock Decline
Multi-state operators lost 4-7% after the agency postponed a key rescheduling hearing without explanation.

Bright candlestick chart showing stock market trends and analysis.
The Market Reaction
Major MSOs declined 4-7% in Monday trading following the DEA announcement. Curaleaf Holdings dropped 6.8%. Trulieve Cannabis fell 5.9%. Green Thumb Industries declined 4.3%. The Cannabis ETF (MSOS) closed down 5.1%, its steepest single-day loss since June.
Trading volume spiked to 180% of the 30-day average. Options activity showed a 3:1 put-to-call ratio—bearish sentiment dominated retail and institutional positioning.
What the DEA Postponed
The agency was scheduled to hold an administrative law judge hearing on October 15, 2026, to review public comments on the proposed Schedule III reclassification. That hearing is now indefinitely delayed. The DEA's one-paragraph notice cited "additional review time required" but provided no revised date.
The notice appeared on the Federal Register docket late Friday, September 27, after market close. Industry counsel first flagged the change Monday morning.
Why This Matters for Operators
Rescheduling to Schedule III would eliminate the IRC Section 280E tax burden that prevents cannabis businesses from deducting ordinary operating expenses. MSOs currently pay effective federal tax rates of 70-85% because 280E disallows deductions for cost of goods sold in Schedule I/II businesses.
Curaleaf's most recent 10-Q estimated that Schedule III status would reduce its annual tax liability by $140-160 million. Trulieve projected $95-110 million in annual savings. Those figures assume rescheduling takes effect by Q1 2027. Each quarter of delay costs the sector roughly $200 million in aggregate tax overpayment.
Timeline Now Uncertain
The postponement means the final rule won't be published before January 2027 at the earliest. Administrative Procedure Act timelines require at least 60 days between the ALJ hearing and a final rule. If the hearing slips to December, the rule can't take effect until March or April.
One variable looms: the November 2026 election. A new administration could withdraw or modify the proposal entirely, though that scenario remains speculative.
What Operators Are Watching
Industry groups are pressing the DEA for a revised hearing date by mid-October. The National Cannabis Industry Association sent a letter Monday requesting clarity on the delay and a commitment to finalize the rule before year-end.
For background on the full rescheduling timeline and stakeholder positions, see the CannIntel topic hub on DEA rescheduling. We'll be watching whether the DEA posts a new hearing date within 30 days or lets the docket go dark into Q4.
For complete background, history, and our ongoing coverage of this story:
Open the CannIntel topic hub →Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Business

Nebraska MMJ Growers Harvest First Crops With No Buyers Yet
Nebraska's first medical cannabis harvests are coming in before any processor, transporter, lab or dispensary exists to take delivery, MJBizDaily reported.

Organigram enters fight for Aurora as Curaleaf bid clock runs
British American Tobacco's stake in Organigram could put the tobacco giant at the center of the Aurora contest before Curaleaf's offer expires Dec. 4.

Tilray Medical Wins Approval for In-House EU-GMP Cannabis Testing
Tilray Medical can now run EU-GMP quality testing in-house, a move that could shift lab costs and batch-release timing, though key details remain undisclosed.
More from the newsroom

Online Hemp Retailer Braces as Federal THC Cap Nears Nov. 12
A Jewish online cannabis retailer profiled by The Forward is preparing for the federal hemp redefinition that takes effect four weeks from now.

Yahoo Reports Medicinal Cannabis Laws Set to Be Strengthened
A Yahoo headline says medicinal cannabis laws will be tightened, but the bill, jurisdiction and effective date remain unidentified.

Yahoo Report: Tests Show Medical Marijuana Fails Insomnia
A Yahoo report says tests found medical marijuana failing against insomnia, but the study details are missing, and the compliance stakes for operators and state programs are not.